Locust Walk’s Overview of AI in Biotech report discusses how AI has profoundly impacted drug discovery and the pharmaceutical industry in the last five years, with AI-derived assets representing nearly half of the preclinical pipeline. AI-enabled drug companies adopt either near-term revenue focused or long-term value-driven business models. Trends show significant growth in AI financings and partnerships, with a 300% increase in annual value from 2019 to 2023. Key themes have emerged as potentially differentiating factors in the next wave of AI technologies, including Explainable AI, Wet-lab validation, and Generative AI.

Understanding these trends and differentiating factors is essential for stakeholders navigating this dynamic and evolving landscape as AI continues to shape the biotech industry.

We invite you to read our report and welcome the opportunity to discuss its contents with you.